Tango Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNGX research report →
Range $35 – $69
Price Chart
About the company
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5).
- CEO
- Malte Peters
- IPO
- 2020
- Employees
- 137
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on TNGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.68B
- P/E
- -15.75
- Fwd P/E
- 21.33
- PEG
- 0.26
- P/S
- 0.00
- P/B
- 3.86
- EV/EBITDA
- -17.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -30.34%
- ROIC
- -22.59%
Latest fiscal year · YoY change
- Revenue
- $62.38M+48.3%
- Gross Profit
- $60.10M+42.9%
- Op Income
- $-111,289,000
- Net Income
- $-101,594,000+22.0%
- EPS
- $-0.87+26.9%
- OCF Growth
- -5.6%
- FCF Growth
- -5.8%
- 52W High
- $34.39
- 52W Low
- $8.30
- 50D MA
- $23.49
- 200D MA
- $23.11
- Beta
- 1.22
- RSI (14)
- 44
- Avg Volume
- 3.43M
No earnings-call transcripts are available for TNGX yet.
- Free Float
- 73.6%
- Shares Outstanding
- 169.46M
- Float Shares
- 124.77M
of shares held by institutions
259 13F filers
Buy/sell ratio 0.27. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 13.90M | ▲ 600.00K |
| Fmr LLC | 13.15M | ▲ 812.78K |
| Blackrock, Inc. | 13.14M | ▲ 704.63K |
| Farallon Capital Management, L.L.C. | 12.28M | ▲ 3.18M |
| Boxer Capital Management, LLC | 10.88M | 0 |
| Goldman Sachs Group Inc | 9.98M | ▲ 4.90M |
| Tcg Crossover Management, LLC | 9.08M | ▼ 1.45M |
| State Street Corp | 7.32M | ▲ 1.34M |
| Siren, L.L.C. | 6.78M | ▲ 604.72K |
| Vanguard Group Inc | 6.75M | ▲ 1.70M |
| Vanguard Capital Management LLC | 6.52M | ▲ 560.26K |
| Trv Gp Iv, LLC | 6.37M | 0 |
Held by 351 ETFs
Biggest fund positions in TNGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Ketchum John B | sell | 3,333 |
| Nov 11, 26 | Crystal Adam | other | 5,000 |
| Nov 11, 26 | Crystal Adam | other | 5,000 |
| Nov 11, 26 | Crystal Adam | sell | 5,000 |
| Nov 2, 26 | Crystal Adam | other | 5,000 |
| Nov 2, 26 | Crystal Adam | other | 5,000 |
| Nov 2, 26 | Crystal Adam | sell | 3,900 |
| Nov 2, 26 | Crystal Adam | sell | 1,100 |
| Nov 2, 26 | Newcomb Jessica | sell | 5,571 |
| Nov 2, 26 | Newcomb Jessica | sell | 1,460 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNGX coverage
Recent articles, reports, and earnings notes.
No research on TNGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNGX report →Tango Therapeutics, Inc. $TNGX Stock Acquired by Fisher Asset Management LLC
defenseworld.net · Nov 15
Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss
defenseworld.net · Nov 11
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
globenewswire.com · Nov 9
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
globenewswire.com · Nov 4
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 3
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
seekingalpha.com · Oct 30
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
seekingalpha.com · Oct 28
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
zacks.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.